# Inmune Bio Inc. (INMB) · Edgar & Edgarette company card

> Inmune Bio (INMB) grew revenue 257% in FY2025 to $0 million, operating margin -94766% against a -15.8% median for biological products, (no diagnostic substances), equity 72.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1711754 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/INMB) · [JSON](https://www.pops4.com/boards/company/INMB.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $50,000 |
| Revenue growth, 1 year | 257.1% |
| Revenue growth per year | -27.5% |
| Operating margin | -94766.0% (prior year -304535.7%) |
| Net margin | -91866.0% |
| Operating cash flow | −$23M |
| Capital spending | $1M |
| Free cash flow | −$24M |
| Cash | $25M |
| Long-term debt | — |
| Total assets | $32M |
| Total equity | $24M |
| Equity ÷ assets | 72.7% |
| Return on equity | -195.3% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -23.76 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$22.6M in FY2025); operating loss: a margin of -94766.0% in FY2025; revenue is hard to predict: its 80% range is ±90%

## Edgarette's reading

Exposure: revenue $50K (FY2025). Experience: revenue up 257.1% on the year, down 27.5% a year over 4 years; operating margin -94766.0%, up from -304535.7%. Soundness: equity 72.7% of assets, return on equity -195.3%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $24K and $436K next year (method v4.1: its own 3-year record of growth weighed at 40% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $19K to $536K. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -94766.0% against a -15.8% median; growth 257.1% against 21.4%.

Range logged 2026-10-09, receipt 795d33b483b003af, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-09-14 ([filing](https://www.sec.gov/Archives/edgar/data/1711754/000121390026099700/0001213900-26-099700-index.htm))

## Recent filings

- S-1 · filed 2026-11-20 · [filing](https://www.sec.gov/Archives/edgar/data/1711754/000121390026122693/0001213900-26-122693-index.htm)
- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1711754/000121390026116359/0001213900-26-116359-index.htm)
- 8-K · filed 2026-10-29 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1711754/000121390026113535/0001213900-26-113535-index.htm)
- 8-K · filed 2026-10-21 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1711754/000121390026111207/0001213900-26-111207-index.htm)
- 8-K · filed 2026-09-14 · 5.02 Departure or Election of Directors; Appointment of Officers; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1711754/000121390026099700/0001213900-26-099700-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1711754/000121390026086135/0001213900-26-086135-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001711754.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1711754

## Cite

POPS4, Edgar & Edgarette: Inmune Bio Inc. (INMB) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/INMB. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

